Gilead, Merck and other big pharmas engaged in illicit “pay-for-delay” deals to retain their lucrative HIV and cholesterol meds supremacy

October 7, 2021

Life Sciences Voice Top Five Newsletter

October 17, 2023

Tecartus Labeling Update Causes Momentary Confusion in FDA Oversight of CAR-T Therapy Safety

January 30, 2024

Must Read

J&J Reports Positive Phase 2/3 Results for Imaavy in Warm Autoimmune Hemolytic Anemia

July 11, 2026

Edgewise Reports Phase 2 CIRRUS-HCM Results for EDG-7500 Ahead of Planned Phase 3 Development

July 11, 2026

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

July 11, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Early research shows that Lilly’s Verve strategy is successful in lowering cholesterol

Kailera Details Nasdaq IPO Plans to Raise Up to $528.5 Million for Obesity Drug Development

Avalyn Files for IPO to Fund Late-Stage Development of Inhaled Lung Disease Therapies

J&J Reports Positive Phase 2/3 Results for Imaavy in Warm Autoimmune Hemolytic Anemia

Bausch + Lomb Ends BL1107 Glaucoma Program After Phase 2 Trial Misses Main Goal

Phase 3 KRYSTAL-10 Study Fails to Meet Primary Endpoints for Krazati in Metastatic Colorectal Cancer

Kailera and Hengrui Report Phase 3 Results for Oral GLP-1 Drug in Obesity and Type 2 Diabetes

Leo Cancer Care Raises $65 Million Series D Round to Expand Upright Radiotherapy Platform

Novartis Set to Buy UK Biotech Myricx For Over $1.1B

In its biggest-ever transaction, Vertex pays $10 billion to buy endocrine disease expert Crinetics

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

Top 10 Barriers to Scaling Genomics Programs in Healthcare

The Rise of AI-Native Biotech Companies

Why Every Pharma Company Is Becoming a Technology Company

Top 10 Reasons Precision Medicine Requires Better Data Integration

Insights

Janssen reports positive topline results for Tremfya in Crohn’s at week 48

Editor Picks

Gilead, Merck and other big pharmas engaged in illicit “pay-for-delay” deals to retain their lucrative HIV and cholesterol meds supremacy

Life Sciences Voice Top Five Newsletter

Tecartus Labeling Update Causes Momentary Confusion in FDA Oversight of CAR-T Therapy Safety

Must Read

J&J Reports Positive Phase 2/3 Results for Imaavy in Warm Autoimmune Hemolytic Anemia

Edgewise Reports Phase 2 CIRRUS-HCM Results for EDG-7500 Ahead of Planned Phase 3 Development

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Hot Topics

About Us

Follow Us